Andrew Yule & Company Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 20, 2025, 7:32 pm

Quick Insight

Andrew Yule & Company Ltd, operating in the Plantations (Tea & Coffee) sector, currently trades at a price of 25.9 with a market cap of ₹1,265 Cr. The company's financial performance reveals a P/E ratio and ROE of 0.84% and 4.89% respectively, highlighting potential undervaluation. However, a negative Net Profit of -3, coupled with a concerning OPM of -42.90%, indicates operational challenges. The shareholder distribution shows strong promoter holding at 89.25%, with minimal FII interest at 0.00%. With reserves of ₹241 Cr and borrowings of ₹105 Cr, the company's financial leverage presents a mixed picture. Investors should closely monitor operational efficiency improvements to gauge sustainability and future profitability amidst the industry dynamics.

Competitors of Andrew Yule & Company Ltd

All Competitor Stocks of Andrew Yule & Company Ltd

Quarterly Result

Last Updated: August 19, 2025, 11:45 pm

Below is a detailed analysis of the quarterly data for Andrew Yule & Company Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 56.00 Cr.. The value appears to be declining and may need further review. It has decreased from 98.00 Cr. (Mar 2025) to 56.00 Cr., marking a decrease of 42.00 Cr..
• For Expenses, as of Jun 2025, the value is 84.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 141.00 Cr. (Mar 2025) to 84.00 Cr., marking a decrease of 57.00 Cr..
• For Operating Profit, as of Jun 2025, the value is -28.00 Cr.. The value appears strong and on an upward trend. It has increased from -42.00 Cr. (Mar 2025) to -28.00 Cr., marking an increase of 14.00 Cr..
• For OPM %, as of Jun 2025, the value is -49.00%. The value appears to be declining and may need further review. It has decreased from -43.00% (Mar 2025) to -49.00%, marking a decrease of 6.00%.
• For Other Income, as of Jun 2025, the value is 60.00 Cr.. The value appears strong and on an upward trend. It has increased from 37.00 Cr. (Mar 2025) to 60.00 Cr., marking an increase of 23.00 Cr..
• For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from -7.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 12.00 Cr..
• For Depreciation, as of Jun 2025, the value is 2.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 15.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from -15.00 Cr. (Mar 2025) to 26.00 Cr., marking an increase of 41.00 Cr..
• For Tax %, as of Jun 2025, the value is 7.00%. The value appears to be increasing, which may not be favorable. It has increased from -19.00% (Mar 2025) to 7.00%, marking an increase of 26.00%.
• For Net Profit, as of Jun 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from -1.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 21.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.41. The value appears strong and on an upward trend. It has increased from -0.01 (Mar 2025) to 0.41, marking an increase of 0.42.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:00 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:53 pm

Below is a detailed analysis of the balance sheet data for Andrew Yule & Company Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 98.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 98.00 Cr..
• For Reserves, as of Mar 2025, the value is 241.00 Cr.. The value appears to be declining and may need further review. It has decreased from 242.00 Cr. (Mar 2024) to 241.00 Cr., marking a decrease of 1.00 Cr..
• For Borrowings, as of Mar 2025, the value is 105.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 114.00 Cr. (Mar 2024) to 105.00 Cr., marking a decrease of 9.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 308.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 257.00 Cr. (Mar 2024) to 308.00 Cr., marking an increase of 51.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 752.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 711.00 Cr. (Mar 2024) to 752.00 Cr., marking an increase of 41.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 192.00 Cr.. The value appears strong and on an upward trend. It has increased from 162.00 Cr. (Mar 2024) to 192.00 Cr., marking an increase of 30.00 Cr..
• For CWIP, as of Mar 2025, the value is 61.00 Cr.. The value appears to be declining and may need further review. It has decreased from 88.00 Cr. (Mar 2024) to 61.00 Cr., marking a decrease of 27.00 Cr..
• For Investments, as of Mar 2025, the value is 244.00 Cr.. The value appears strong and on an upward trend. It has increased from 219.00 Cr. (Mar 2024) to 244.00 Cr., marking an increase of 25.00 Cr..
• For Other Assets, as of Mar 2025, the value is 256.00 Cr.. The value appears strong and on an upward trend. It has increased from 242.00 Cr. (Mar 2024) to 256.00 Cr., marking an increase of 14.00 Cr..
• For Total Assets, as of Mar 2025, the value is 752.00 Cr.. The value appears strong and on an upward trend. It has increased from 711.00 Cr. (Mar 2024) to 752.00 Cr., marking an increase of 41.00 Cr..

Notably, the Reserves (241.00 Cr.) exceed the Borrowings (105.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Andrew Yule & Company Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -0.06. This value is below the healthy minimum of 5. It has increased from -0.97 (Mar 24) to -0.06, marking an increase of 0.91.
• For Diluted EPS (Rs.), as of Mar 25, the value is -0.06. This value is below the healthy minimum of 5. It has increased from -0.97 (Mar 24) to -0.06, marking an increase of 0.91.
• For Cash EPS (Rs.), as of Mar 25, the value is -0.07. This value is below the healthy minimum of 3. It has increased from -1.17 (Mar 24) to -0.07, marking an increase of 1.10.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.93. It has decreased from 6.94 (Mar 24) to 6.93, marking a decrease of 0.01.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 6.93. It has decreased from 6.94 (Mar 24) to 6.93, marking a decrease of 0.01.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 6.38. It has increased from 6.34 (Mar 24) to 6.38, marking an increase of 0.04.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has increased from -1.04 (Mar 24) to 0.00, marking an increase of 1.04.
• For PBIT / Share (Rs.), as of Mar 25, the value is -0.44. This value is below the healthy minimum of 0. It has increased from -1.18 (Mar 24) to -0.44, marking an increase of 0.74.
• For PBT / Share (Rs.), as of Mar 25, the value is -0.58. This value is below the healthy minimum of 0. It has increased from -1.50 (Mar 24) to -0.58, marking an increase of 0.92.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -0.52. This value is below the healthy minimum of 2. It has increased from -1.31 (Mar 24) to -0.52, marking an increase of 0.79.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -0.05. This value is below the healthy minimum of 2. It has increased from -0.97 (Mar 24) to -0.05, marking an increase of 0.92.
• For PBDIT Margin (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 10. It has increased from -16.37 (Mar 24) to 0.00, marking an increase of 16.37.
• For PBIT Margin (%), as of Mar 25, the value is -7.03. This value is below the healthy minimum of 10. It has increased from -18.62 (Mar 24) to -7.03, marking an increase of 11.59.
• For PBT Margin (%), as of Mar 25, the value is -9.14. This value is below the healthy minimum of 10. It has increased from -23.62 (Mar 24) to -9.14, marking an increase of 14.48.
• For Net Profit Margin (%), as of Mar 25, the value is -8.19. This value is below the healthy minimum of 5. It has increased from -20.73 (Mar 24) to -8.19, marking an increase of 12.54.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -0.91. This value is below the healthy minimum of 8. It has increased from -15.32 (Mar 24) to -0.91, marking an increase of 14.41.
• For Return on Networth / Equity (%), as of Mar 25, the value is -0.83. This value is below the healthy minimum of 15. It has increased from -13.99 (Mar 24) to -0.83, marking an increase of 13.16.
• For Return on Capital Employeed (%), as of Mar 25, the value is -5.63. This value is below the healthy minimum of 10. It has increased from -14.42 (Mar 24) to -5.63, marking an increase of 8.79.
• For Return On Assets (%), as of Mar 25, the value is -0.37. This value is below the healthy minimum of 5. It has increased from -6.68 (Mar 24) to -0.37, marking an increase of 6.31.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.31. This value is within the healthy range. It has decreased from 0.33 (Mar 24) to 0.31, marking a decrease of 0.02.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.42. There is no change compared to the previous period (Mar 24) which recorded 0.42.
• For Current Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1.5. It has decreased from 0.70 (Mar 24) to 0.66, marking a decrease of 0.04.
• For Quick Ratio (X), as of Mar 25, the value is 0.55. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 24) to 0.55, marking a decrease of 0.04.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.98. This value is below the healthy minimum of 4. It has increased from 2.36 (Mar 24) to 2.98, marking an increase of 0.62.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 3. It has increased from -3.27 (Mar 24) to 0.00, marking an increase of 3.27.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.89. This value is below the healthy minimum of 3. It has increased from -3.11 (Mar 24) to -2.89, marking an increase of 0.22.
• For Enterprise Value (Cr.), as of Mar 25, the value is 1,325.93. It has decreased from 1,776.01 (Mar 24) to 1,325.93, marking a decrease of 450.08.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 4.25. This value exceeds the healthy maximum of 3. It has decreased from 5.73 (Mar 24) to 4.25, marking a decrease of 1.48.
• For EV / EBITDA (X), as of Mar 25, the value is -51,392.68. This value is below the healthy minimum of 5. It has decreased from -35.00 (Mar 24) to -51,392.68, marking a decrease of 51,357.68.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 5.49 (Mar 24) to 4.04, marking a decrease of 1.45.
• For Price / BV (X), as of Mar 25, the value is 3.71. This value exceeds the healthy maximum of 3. It has decreased from 5.01 (Mar 24) to 3.71, marking a decrease of 1.30.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.04. This value exceeds the healthy maximum of 3. It has decreased from 5.49 (Mar 24) to 4.04, marking a decrease of 1.45.
• For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has increased from -0.02 (Mar 24) to 0.00, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness